|
|
|
|
CME Program Alert: Prevention of Acute Radiation Induced Proctosigmoiditis (RIPS)
SOURCE: CECity.com, Inc.
5:54AM, April 18, 2006
Homestead, Pennsylvania, April, 18, 2006 -- The University of Texas Medical Branch at Galveston (UTMB) and SOMA Medical Education Company are pleased to announce the launch of their jointly sponsored e-learning CME activity entitled Prevention of Acute Radiation Induced Proctosigmoiditis (RIPS). This activity is made possible by an unrestricted educational grant from Salix Pharmaceuticals, Inc.
Available online at http://www.cemedicus.com/rips, the program informs participants about the prevalence of acute radiation induced proctosigmoiditis, and describes current and prior approaches to its management. Recent advances in amelioration of this toxicity are described in the context of earlier failed trials, with an emphasis on unique mechanisms of the agents employed. Radiation Oncologists, Oncologists and other healthcare professionals who treat patients receiving pelvic radiotherapy are invited to participate in the free program led by Program Chairperson, Christopher D. Jahraus, M.D., Assistant Professor of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Upon completion of this activity, participants should be able to recognize the prevalence of acute radiation induced proctosigmoiditis (RIPS) among pelvic radiotherapy patients and the need for specific questioning regarding such symptoms, describe the likely reasons most prior trials of pharmacologic agents for RIPS have failed; differentiate the structural and mechanistic similarities and differences between the past and present agents utilized in RIPS/radiation enteritis treatment, and define the supporting evidence for current treatments and treatment strategy in RIPS prevention.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Texas Medical Branch at Galveston (UTMB) and SOMA Medical Education Company. The University of Texas Medical Branch at Galveston is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. UTMB designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Each physician should claim only those credits commensurate with the extent of their participation in the activity.
Disclosure Statements
UTMB and SOMA Medical Education Company have conflict of interest policies that require course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials, and any discussions of unlabeled or investigational use of any commercial product or device not yet approved in the United States. It is not assumed these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.
Off-Label Disclosure Statement
This educational activity contains discussion of published and/or investigational use of agents that are not indicated by the FDA. The faculty, UTMB, and SOMA Medical Education Company do not recommend use of any agent outside of labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
CE Medicus® is powered by and is a Registered Service mark of CECity.com, Inc®.
For additional information visit
www.CEMedicus.com/rips
|
|
|
|
|
|
We subscribe to the HONcode principles of the Health On the Net Foundation